<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02424006</url>
  </required_header>
  <id_info>
    <org_study_id>201503-001</org_study_id>
    <secondary_id>LVPEI-RHCIII-MPC CORNEA</secondary_id>
    <nct_id>NCT02424006</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the RHCIII-MPC Biosynthetic Cornea in Patients Requiring Anterior Lamellar Keratoplasty</brief_title>
  <official_title>A Prospective, Randomized, Open Label Clinical Trial to Evaluate the Safety and Effectiveness of the RHCIII-MPC Biosynthetic Cornea Compared to Human Cornea in Patients Requiring Anterior Lamellar Keratoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>L.V. Prasad Eye Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>L.V. Prasad Eye Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study safety and effectiveness of bioengineered cornea comprising of interpenetrating
      networks of recombinant human type III collagen and synthetic phospholipid -
      phosphorylcholine - will be tested in patients with corneal scars (leukomas) after infection,
      trauma or keratoconus. Control group will consist of patients with the same condition who
      will undergo corneal transplantation - current standard of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently developed and passed extensive pre-clinical testing
      collagen-phosphorylcholine(RHCIII-MPC) corneal substitute will be implanted in patient's
      corneas with corneal scar (leukoma) developed after infection, trauma or keratoconus using
      anterior lamellar keratoplasty technique, i.e. once patient's diseased anterior part of
      cornea is removed, either manually or with assistance of femtosecond laser, it will be
      substituted with proposed transparent implant. Control patients with same condition will be
      grafted with human donor cornea using the same surgical technique.

      The investigators will test the safety and the effectiveness of developed biosynthetic
      corneas. Overall 20 patients are planned to recruit. They will be randomized in two groups -
      10 patients will undergo RHCIII-MPC cornea implantation, another 10 will be impanted with
      human donor cornea. The patients will be follow-uped for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (Degree of eye inflammation)</measure>
    <time_frame>12 months</time_frame>
    <description>Degree of eye inflammation based on conjunctival injection, perifocal corneal haze, aqueous humor transparency, increased intraocular pressure and self reported postoperative pain. Each item is scored 0-4: 0 = no symptom, 4 = severe symptom.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biocompatability, degree of haze and/or vascularisation measured on a scale 0-4</measure>
    <time_frame>12 months</time_frame>
    <description>The implant/donor cornea graft biocompatability will be checked by degree of haze and/or vascularisation measured on a scale 0-4 (0 - transparent implant/graft, no vessels, 4 - haze does not allow visualizing pupil, vessels enter entire surface of implant/graft)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity measured by LogMAR</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leukoma</condition>
  <arm_group>
    <arm_group_label>RHCIII-MPC cornea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of this arm will undergo RHCIII-MPC bioengineered cornea transplantation using anterior lamellar keratoplasty technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donor cornea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients of this arm will undergo human donor cornea transplantation using anterior lamellar keratoplasty technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RHCIII-MPC cornea</intervention_name>
    <description>Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.</description>
    <arm_group_label>RHCIII-MPC cornea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Donor cornea</intervention_name>
    <description>Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.</description>
    <arm_group_label>Donor cornea</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must sign and be given a copy of the written Informed Consent form.

          -  Subjects with best corrected distance visual acuity +1.0 LogMAR or worse as a result
             of corneal scar due to infection, injury or keratoconus in the operative eye.

          -  Subjects must be willing and able to return for scheduled follow-up examinations for
             12 months after surgery.

        Exclusion Criteria:

          -  Subjects with severe or life-threatening systemic disease.

          -  Subjects with uncontrolled hypertension.

          -  Subjects with uncontrolled diabetes or insulin-dependent diabetes.

          -  Subjects with glaucoma in either eye.

          -  Subjects with marked microphthalmos or aniridia in either eye.

          -  Subjects with any other serious ocular pathology, serious ocular complications at the
             time of surgery underlying serious medical conditions, based on the investigator's
             medical judgment.

          -  Subjects which are or lactating or who plan to become pregnant over the course of the
             clinical investigation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virender S Sangwan, MBBS, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>LV Prasad Eye Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virender S Sangwan, MBBS, MS</last_name>
    <phone>+9140-30612632</phone>
    <email>vsangwan@lvpei.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>L V Prasad Eye Institute, Centre for Ocular Regeneration</name>
      <address>
        <city>Hyderabad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Virender S Sangwan, MD</last_name>
      <phone>+9140-30612632</phone>
      <email>vsangwan@lvpei.org</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Liu W, Deng C, McLaughlin CR, Fagerholm P, Lagali NS, Heyne B, Scaiano JC, Watsky MA, Kato Y, Munger R, Shinozaki N, Li F, Griffith M. Collagen-phosphorylcholine interpenetrating network hydrogels as corneal substitutes. Biomaterials. 2009 Mar;30(8):1551-9. doi: 10.1016/j.biomaterials.2008.11.022. Epub 2008 Dec 20.</citation>
    <PMID>19097643</PMID>
  </results_reference>
  <results_reference>
    <citation>Fagerholm P, Lagali NS, Ong JA, Merrett K, Jackson WB, Polarek JW, Suuronen EJ, Liu Y, Brunette I, Griffith M. Stable corneal regeneration four years after implantation of a cell-free recombinant human collagen scaffold. Biomaterials. 2014 Mar;35(8):2420-7. doi: 10.1016/j.biomaterials.2013.11.079. Epub 2013 Dec 25.</citation>
    <PMID>24374070</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>L.V. Prasad Eye Institute</investigator_affiliation>
    <investigator_full_name>Virender S Sangwan, MBBS, MS</investigator_full_name>
    <investigator_title>Director, Center for Ocular Regeneration</investigator_title>
  </responsible_party>
  <keyword>keratoplasty</keyword>
  <keyword>bioengineered cornea</keyword>
  <keyword>donor cornea</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

